American Biotech Innovation Alliance

What American Biotech Innovation Alliance does

American Biotech Innovation Alliance (ABIA) is a privately organized coalition and policy-advocacy body led by emerging and mid-sized biotech companies. Its stated mission is to strengthen U.S. leadership across the full biotech innovation pipeline — from R&D investment to manufacturing and workforce development — through a published Vision 2030: A National Innovation Plan for American Biotech. ABIA does not sell products or license technology; rather, it serves as the collective voice of its member companies in shaping national biotech policy, regulatory modernization, supply chain resilience, and patient-centric scientific innovation.

The organization's commercial engine is a membership subscription model built around the Founding Fifty initiative, a time-limited campaign to recruit up to 50 founding members who pay dues and receive exclusive early-member benefits, legacy recognition, and a role in defining the Vision 2030 strategy. Its publicly disclosed membership includes 27 organizations — ranging from large biotech companies (Moderna, Rocket Pharmaceuticals, CG Oncology, MannKind, Mesoblast) to smaller specialty firms and advisory/strategy firms (BGB Group, CG Life, SSI Strategy) — across modalities spanning oncology, gene therapy, metabolic disease, and rare disease. Distribution is purely domestic and direct: the biotechstrong.us website hosts a contact form segmented into Founding Fifty, partnership, and general inquiry funnels.

Disclosed quantitative context used to frame ABIA's public narrative includes 55% U.S. share of global biopharma R&D, 80% China control of global API production, 30% of FDA-approved drug workflows offshored to Chinese CDMOs, and 72% of 2024 FDA novel drug approvals originating from small and mid-sized companies. The organization is described as operating but no founding date, headcount, revenue, or external funding is disclosed, and no parent company, subsidiaries, patents, or technology products are evidenced.

Name

American Biotech Innovation Alliance

Legal name

American Biotech Innovation Alliance

Website

https://biotechstrong.us

Company type

Private

Operating status

Operating

Short description

American Biotech Innovation Alliance (ABIA) is a privately organized, member-funded coalition of emerging biotech companies that drives the Vision 2030 national innovation strategy through its Founding Fifty membership program, serving U.S. industry advocacy, regulatory modernization, and supply chain resilience.

Ownership category

akta.pro rank

Product category

Biotech Industry Advocacy

NAICS

Business Associations (813910)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Biotech policy advocacy
• Industry coalition building
• Membership association
• Regulatory advocacy
• National innovation strategy

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Membership Dues: The organization recruits Founding Fifty members who pay dues in exchange for strategic benefits including defining Vision 2030 strategy, legacy recognition, and exclusive early-member benefits.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

ABIA is an industry coalition and advocacy organization led by emerging biotech companies. It sells membership in its "Founding Fifty" coalition initiative, which gives member organizations the ability to help define the Vision 2030 national innovation strategy for American biotech, receive legacy recognition as founding coalition members, and obtain exclusive early-member benefits. The organization is not a product vendor — its core deliverable is coalition-based policy advocacy, regulatory modernization support, and ecosystem strengthening across R&D, manufacturing, and workforce.

Product overview

American Biotech Innovation Alliance (ABIA) is not a product company but rather an industry coalition and membership organization. The organization does not offer distinct commercial products or services; instead, it operates as an alliance focused on advancing American biotech leadership through advocacy, strategy development, and ecosystem strengthening under the Vision 2030 initiative. Membership programs such as the 'Founding Fifty' offer strategic benefits but are not product offerings in the traditional sense.

Differentiator

Problem solved

Functional benefit

Products and services

• Founding Fifty Membership A coalition membership program for biotech companies that provides the ability to help define the Vision 2030 national innovation strategy for American biotech, earn legacy recognition as a founding coalition member, and receive exclusive early-member benefits. Targeted at emerging and established U.S. biotech and biopharmaceutical companies seeking collective policy influence on regulatory modernization, supply chain security, and innovation pipeline strengthening.

Quantifiable outcome

• 72% of FDA novel drug approvals came from small and mid-sized companies in 2024
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

26 partnerships are on record, tiered core.

• BGB GroupcoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• BiomedicacoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• CG LifecoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• CG OncologycoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• Coherus OncologycoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• Endeavor BioMedicinescoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• Gamida CellcoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• INmune BiocoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• KL MidoricoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• Mahzi TherapeuticscoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• MannKindcoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• Mercury BiocoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• MesoblastcoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• Milestone HeightscoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• ModernacoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• OS TherapiescoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• PharvariscoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• Praxis Precision MedicinescoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• Prilenia TherapeuticscoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• Promontory TherapeuticscoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• RezolutecoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• Rocket PharmaceuticalscoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• Saol TherapeuticscoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• Sebela PharmaceuticalscoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• Soleno TherapeuticscoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy
• SSI StrategycoreStrategic or Co-development PartnerMember of ABIA's Founding Fifty coalition representing biotech companies shaping Vision 2030 national innovation strategy

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• MassBio: MassBio is a state-level biotech industry association representing the Massachusetts life sciences cluster. While geographically narrower than ABIA, it operates the same membership-coalition model for biotech advocacy, talent development, and ecosystem support — directly comparable in structure and value proposition.
• Council of State Bioscience Associations (CSBA): CSBA is a coalition of state-level biotech associations across the U.S., providing a coordinating body for regional advocacy organizations. It is a direct structural peer to ABIA in coalition model and is a potential partner or competitor for member biotechs depending on how ABIA's national strategy interacts with state-level policy efforts.
• California Life Sciences: California Life Sciences is the state's largest life sciences membership organization, representing hundreds of biotech and pharma members. It is a direct structural peer to ABIA — a regional coalition that advocates for biotech policy, workforce, and innovation — and is a relevant benchmark for ABIA's scaling ambitions.
• Alliance for Regenerative Medicine (ARM): ARM is an international multi-stakeholder advocacy organization specifically for the regenerative medicine and advanced therapies sector. It is a direct peer in operating model (membership-led policy advocacy for a defined biotech sub-segment) and is among several ABIA member companies' trade groups.
• Biotechnology Innovation Organization (BIO): BIO is the largest U.S. biotech trade association, representing ~1,000 member companies across the biotech ecosystem. It is the most direct peer to ABIA in mission (industry advocacy, regulatory modernization, policy) and target base (biotech companies), though BIO's membership is broader and includes large-cap pharma.

Broad incumbents

• AdvaMed: AdvaMed is the leading U.S. medical device industry trade association. It is a broad incumbent in the same life sciences advocacy ecosystem as ABIA, with a similar member-coalition model and policy focus, but its end market is medical devices rather than biotech therapeutics.
• Pharmaceutical Research and Manufacturers of America (PhRMA): PhRMA represents the largest U.S. pharmaceutical companies with hundreds of millions in annual lobbying spend. It is a broad incumbent in the same advocacy space as ABIA, but its member base skews to large-cap pharma rather than emerging biotech — the niche ABIA is targeting.

Others

• National Venture Capital Association (NVCA): NVCA is the trade association for the U.S. venture capital industry, including investors that fund the emerging biotechs ABIA represents. It is an adjacent peer — not a direct competitor, but a policy ally whose advocacy on R&D tax, FDA pathways, and capital formation overlaps materially with ABIA's agenda.
• American Association of Pharmaceutical Scientists (AAPS): AAPS is a professional scientific association for pharmaceutical scientists, with a membership model and policy advocacy footprint in pharmaceutical R&D. It is thematically adjacent to ABIA's biotech regulatory mission but focuses on scientific professionals rather than corporate members.
• PhRMA Foundation: The PhRMA Foundation funds pharmaceutical research and workforce development, focused on advancing the scientific pipeline that supports the U.S. drug industry. It is adjacent to ABIA in mission (biotech workforce and innovation pipeline) and could be a complementary funding or partnering organization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/american-biotech-innovation-alliance

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about American Biotech Innovation Alliance